Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01784861 · ClinicalTrials.gov registry record · Phase 1
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01784861 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 23 participants.
The verdict
NCT01784861, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is to evaluate the combination of an investigational drug X-82 with everolimus in the treatment of pancreatic neuroendocrine tumors.
Interventions
- DRUG Everolimus
- DRUG X-82
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-05-03 |
| Est. Completion | 2020-08-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01784861
The ClinicalTrials.gov registry entry for NCT01784861 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT01784861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01784861 about?
NCT01784861 is a clinical study titled "VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors". This study is to evaluate the combination of an investigational drug X-82 with everolimus in the treatment of pancreatic neuroendocrine tumors.
What is the current status of trial NCT01784861?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2013-05-03. Estimated completion is 2020-08-19.
What interventions are being tested in trial NCT01784861?
The interventions under investigation include: Everolimus (DRUG), X-82 (DRUG).
Who is sponsoring clinical trial NCT01784861?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.